Frequency and new-onset rates of nausea and fatigue in ¹⁷⁷Lu-PSMA therapy with standardized premedication
Nuklearmedizin - NuclearMedicine · 01.10.2026 · 65 (05) · 303-311
DOI: 10.1055/a-2902-0532 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.10.2026. Verfasst von Wolfram A Bosbach und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Bern, Inselspital, Bern, University Hospital, Switzerland, Bern. Hauptthemen laut MEDLINE: Nausea, Fatigue, Dipeptides, Premedication. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
PSMA-based radioligand therapy (PSMA-RLT) for metastatic castration-resistant prostate cancer (mCRPC) is associated with nausea, vomiting, and fatigue. We evaluated whether standardized premedication with glucocorticoids and antiemetics reduces these side effects. In this retrospective multicentre study, 67 mCRPC patients received 322 cycles of 177Lu-PSMA-617 at three Swiss centres. All patients received 8 mg dexamethasone and 8 mg ondansetron intravenously 30 minutes before therapy. Side effects were assessed using study-specific questionnaires (195/322 returned; 61%). Baseline symptoms were documented using EORTC questionnaires in 30 patients. Biochemical response was evaluated in 36 patients using PCWG3 criteria. Absolute side effect rates were: nausea within 3 days 20.9%, inter-cycle nausea 35.8%, vomiting 10.4%, and fatigue 67.2%. After correction for baseline symptoms, estimated new-onset rates were lower: 16.3%, 26.1%, 7.0%, and 6.7%, respectively. Early nausea significantly predicted inter-cycle nausea (p=0.02). Side effects followed a U-shaped pattern across cycles. No significant association was observed between side effects and PCWG3 biochemical response, though statistical power was limited. Absolute rates of nausea and fatigue were comparable to the VISION trial. However, new-onset rates of these two side effects were substantially lower after accounting for baseline symptoms. A protective effect of premedication with glucocorticoids and antiemetics could be the reason for this, but requires confirmation in prospective controlled studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Bern, Inselspital, Bern, University Hospital, Switzerland, Bern.
- Ente Ospedaliero Cantonale, Imaging Institute of Southern Switzerland, Switzerland, Bellinzona.
- Cantonal Hospital Baden, Partner hospital for research and teaching of the Medical Faculty of the University of Zurich, Department of Nuclear Medicine, Switzerland, Baden.
- Università della Svizzera Italiana (USI), Faculty of Biomedical Sciences, Switzerland, Lugano.
- University of Zurich, Department of Nuclear Medicine, University Hospital Zurich, Switzerland, Zürich.
- ETH Zurich, Department of Health Sciences and Technology, Switzerland, Zurich.
ORCID-Profile: Wolfram A Bosbach
Zitieren
APA
Bosbach, W. A., Sriramachandran, K., Gözlügöl, N., Rominger, A., Cuzzocrea, M., Pop, S. G., Paone, G., Burger, I. A., & Afshar-Oromieh, A. (2026). Frequency and new-onset rates of nausea and fatigue in ¹⁷⁷Lu-PSMA therapy with standardized premedication. Nuklearmedizin - NuclearMedicine, 65(05), 303-311. https://doi.org/10.1055/a-2902-0532
Vancouver
Bosbach WA, Sriramachandran K, Gözlügöl N, Rominger A, Cuzzocrea M, Pop SG, et al. Frequency and new-onset rates of nausea and fatigue in ¹⁷⁷Lu-PSMA therapy with standardized premedication. Nuklearmedizin - NuclearMedicine. 2026;65(05):303-311. doi:10.1055/a-2902-0532
BibTeX
@article{Bosbach2026,
author = {Bosbach, Wolfram A and Sriramachandran, Karene and Gözlügöl, Nasir and Rominger, Axel and Cuzzocrea, Marco and Pop, Sabin G and Paone, Gaetano and Burger, Irene A and Afshar-Oromieh, Ali},
title = {Frequency and new-onset rates of nausea and fatigue in ¹⁷⁷Lu-PSMA therapy with standardized premedication},
journal = {Nuklearmedizin - NuclearMedicine},
year = {2026},
volume = {65},
number = {05},
pages = {303--311},
doi = {10.1055/a-2902-0532}
}
EUVIMED